CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 157 enrolled
Drug / intervention
Atorvastatin 20 mg +5 moredrug
Likely dose
Atorvastatin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00474240
NCT00474240Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia

Aegerion Pharmaceuticals, Inc.·interventional·Posted May 16, 2007·Updated Mar 20, 2018

In Brief

A Phase 2 clinical trial evaluating Atorvastatin 20 mg, AEGR-733 5 mg, and 4 other interventions for Hypercholesterolemia. Completed, enrolled 157 participants across 17 sites.

Detailed Summary

The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 16, 2007
Enrollment StartApr 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.1 years ago

Interventions

Atorvastatin 20 mgdrug

AEGR-733 5 mgdrug

AEGR-733 10 mgdrug

Placebodrug

AEGR-733 5 mg + atorvastatin 20 mgdrug

AEGR-733 10 mg + atorvastatin 20 mgdrug